PE20142113A1 - Analogos de glucagon - Google Patents
Analogos de glucagonInfo
- Publication number
- PE20142113A1 PE20142113A1 PE2014000970A PE2014000970A PE20142113A1 PE 20142113 A1 PE20142113 A1 PE 20142113A1 PE 2014000970 A PE2014000970 A PE 2014000970A PE 2014000970 A PE2014000970 A PE 2014000970A PE 20142113 A1 PE20142113 A1 PE 20142113A1
- Authority
- PE
- Peru
- Prior art keywords
- ser
- leu
- lys
- asp
- absent
- Prior art date
Links
- MASNOZXLGMXCHN-ZLPAWPGGSA-N glucagon Chemical class C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)C(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C1=CC=CC=C1 MASNOZXLGMXCHN-ZLPAWPGGSA-N 0.000 title abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 2
- 102000007446 Glucagon-Like Peptide-1 Receptor Human genes 0.000 abstract 1
- 108010086246 Glucagon-Like Peptide-1 Receptor Proteins 0.000 abstract 1
- 208000008589 Obesity Diseases 0.000 abstract 1
- TUCNEACPLKLKNU-UHFFFAOYSA-N acetyl Chemical class C[C]=O TUCNEACPLKLKNU-UHFFFAOYSA-N 0.000 abstract 1
- 150000001413 amino acids Chemical class 0.000 abstract 1
- 206010012601 diabetes mellitus Diseases 0.000 abstract 1
- 235000020824 obesity Nutrition 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/605—Glucagons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/26—Glucagons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Diabetes (AREA)
- Endocrinology (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Epidemiology (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Immunology (AREA)
- Genetics & Genomics (AREA)
- Toxicology (AREA)
- Biochemistry (AREA)
- Emergency Medicine (AREA)
- Child & Adolescent Psychology (AREA)
- Pain & Pain Management (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Rheumatology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161579888P | 2011-12-23 | 2011-12-23 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20142113A1 true PE20142113A1 (es) | 2014-12-03 |
Family
ID=47594620
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2014000970A PE20142113A1 (es) | 2011-12-23 | 2012-12-19 | Analogos de glucagon |
Country Status (20)
| Country | Link |
|---|---|
| US (2) | US20130316941A1 (OSRAM) |
| EP (1) | EP2793931A2 (OSRAM) |
| JP (1) | JP2015502380A (OSRAM) |
| KR (1) | KR20140114845A (OSRAM) |
| CN (1) | CN104144696A (OSRAM) |
| AP (2) | AP2014007797A0 (OSRAM) |
| AU (1) | AU2012357739A1 (OSRAM) |
| BR (1) | BR112014015681A2 (OSRAM) |
| CA (1) | CA2858949A1 (OSRAM) |
| EA (1) | EA201490982A1 (OSRAM) |
| HK (1) | HK1200369A1 (OSRAM) |
| IL (1) | IL232800A0 (OSRAM) |
| IN (1) | IN2014CN04401A (OSRAM) |
| MA (1) | MA35864B1 (OSRAM) |
| MX (1) | MX2014007120A (OSRAM) |
| PE (1) | PE20142113A1 (OSRAM) |
| PH (1) | PH12014501336A1 (OSRAM) |
| SG (1) | SG11201403377QA (OSRAM) |
| TN (1) | TN2014000224A1 (OSRAM) |
| WO (1) | WO2013092703A2 (OSRAM) |
Families Citing this family (49)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9156901B2 (en) | 2009-07-13 | 2015-10-13 | Ditte Riber | Acylated glucagon analogues |
| UY33462A (es) | 2010-06-23 | 2012-01-31 | Zealand Pharma As | Analogos de glucagon |
| AU2011269430A1 (en) | 2010-06-24 | 2013-01-10 | Zealand Pharma A/S | Glucagon analogues |
| IN2014MN02304A (OSRAM) | 2012-05-03 | 2015-08-07 | Zealand Pharma As | |
| EP2664374A1 (en) * | 2012-05-15 | 2013-11-20 | F. Hoffmann-La Roche AG | Lysin-glutamic acid dipeptide derivatives |
| CN109456400A (zh) | 2012-07-23 | 2019-03-12 | 西兰制药公司 | 胰高血糖素类似物 |
| TWI608013B (zh) | 2012-09-17 | 2017-12-11 | 西蘭製藥公司 | 升糖素類似物 |
| UA116217C2 (uk) | 2012-10-09 | 2018-02-26 | Санофі | Пептидна сполука як подвійний агоніст рецепторів glp1-1 та глюкагону |
| SG10201705097PA (en) | 2012-12-21 | 2017-07-28 | Sanofi Sa | Functionalized exendin-4 derivatives |
| GB201315335D0 (en) * | 2013-08-29 | 2013-10-09 | Of Singapore | Amino diacids containing peptide modifiers |
| RS57632B1 (sr) * | 2013-10-17 | 2018-11-30 | Zealand Pharma As | Acilovani analozi glukagona |
| US9988429B2 (en) | 2013-10-17 | 2018-06-05 | Zealand Pharma A/S | Glucagon analogues |
| JP2017503474A (ja) | 2013-11-06 | 2017-02-02 | ジーランド ファーマ アクティーゼルスカブ | グルカゴン−ｇｌｐ−１−ｇｉｐトリプルアゴニスト化合物 |
| CN105849122B (zh) | 2013-11-06 | 2021-04-30 | 西兰制药公司 | Gip-glp-1双重激动剂化合物及方法 |
| TW201609797A (zh) | 2013-12-13 | 2016-03-16 | 賽諾菲公司 | 雙重ｇｌｐ－１／升糖素受體促效劑 |
| EP3080154B1 (en) | 2013-12-13 | 2018-02-07 | Sanofi | Dual glp-1/gip receptor agonists |
| TW201609796A (zh) | 2013-12-13 | 2016-03-16 | 賽諾菲公司 | 非醯化之艾塞那肽－４（ｅｘｅｎｄｉｎ－４）胜肽類似物 |
| WO2015086728A1 (en) | 2013-12-13 | 2015-06-18 | Sanofi | Exendin-4 peptide analogues as dual glp-1/gip receptor agonists |
| TW201625668A (zh) * | 2014-04-07 | 2016-07-16 | 賽諾菲公司 | 作為胜肽性雙重ｇｌｐ－１／昇糖素受體激動劑之艾塞那肽－４衍生物 |
| TW201625670A (zh) * | 2014-04-07 | 2016-07-16 | 賽諾菲公司 | 衍生自ｅｘｅｎｄｉｎ－４之雙重ｇｌｐ－１／升糖素受體促效劑 |
| TW201625669A (zh) | 2014-04-07 | 2016-07-16 | 賽諾菲公司 | 衍生自艾塞那肽－４（Ｅｘｅｎｄｉｎ－４）之肽類雙重ＧＬＰ－１／升糖素受體促效劑 |
| US9932381B2 (en) | 2014-06-18 | 2018-04-03 | Sanofi | Exendin-4 derivatives as selective glucagon receptor agonists |
| TWI705973B (zh) | 2014-10-29 | 2020-10-01 | 丹麥商西蘭製藥公司 | Ｇｉｐ促效劑化合物及方法 |
| JOP20200119A1 (ar) * | 2015-01-09 | 2017-06-16 | Lilly Co Eli | مركبات مساعد مشترك من gip وglp-1 |
| MX376200B (es) | 2015-02-17 | 2025-03-07 | Amphastar Pharmaceuticals Inc | Formulacion en polvo nasal para el tratamiento de hipoglicemia. |
| PE20180497A1 (es) | 2015-03-18 | 2018-03-09 | Zealand Pharma As | Analogos de amilina |
| WO2016168388A2 (en) | 2015-04-14 | 2016-10-20 | Palatin Technologies, Inc. | Therapies for obesity, diabetes and related indications |
| PL3283507T3 (pl) | 2015-04-16 | 2020-05-18 | Zealand Pharma A/S | Acylowany analog glukagonu |
| AR105319A1 (es) | 2015-06-05 | 2017-09-27 | Sanofi Sa | Profármacos que comprenden un conjugado agonista dual de glp-1 / glucagón conector ácido hialurónico |
| WO2016198628A1 (en) | 2015-06-12 | 2016-12-15 | Sanofi | Non-acylated exendin-4 derivatives as dual glp-1/glucagon receptor agonists |
| WO2016198624A1 (en) | 2015-06-12 | 2016-12-15 | Sanofi | Exendin-4 derivatives as trigonal glp-1/glucagon/gip receptor agonists |
| AR105284A1 (es) | 2015-07-10 | 2017-09-20 | Sanofi Sa | Derivados de exendina-4 como agonistas peptídicos duales específicos de los receptores de glp-1 / glucagón |
| TWI622596B (zh) * | 2015-10-26 | 2018-05-01 | 美國禮來大藥廠 | 升糖素受體促效劑 |
| US11179444B2 (en) | 2016-06-09 | 2021-11-23 | Amidebio, Llc | Glucagon analogs and methods of use thereof |
| MA45843B1 (fr) | 2016-08-05 | 2021-06-30 | Boehringer Ingelheim Int | Dérivés d'oxadiazolopyridine utilisés comme inhibiteurs de la ghréline o-acyl transférase (chèvre) |
| TWI784968B (zh) | 2016-09-09 | 2022-12-01 | 丹麥商西蘭製藥公司 | 澱粉素類似物 |
| EP3551651B1 (en) * | 2016-12-09 | 2024-03-06 | Zealand Pharma A/S | Acylated glp-1/glp-2 dual agonists |
| CN116854804A (zh) * | 2017-08-16 | 2023-10-10 | 东亚St株式会社 | 酰化胃泌酸调节素肽类似物 |
| JP7150032B2 (ja) | 2018-02-02 | 2022-10-07 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | グレリンｏ－アシルトランスフェラーゼ（ｇｏａｔ）阻害薬として使用するためのヘテロシクリル置換オキサジアゾロピリジン誘導体 |
| EP3746449B1 (en) | 2018-02-02 | 2022-03-30 | Boehringer Ingelheim International GmbH | Pyrazole- and indazole-substituted oxadiazolopyridine derivatives for use as ghrelin o-acyl transferase (goat) inhibitors |
| CN111655700B (zh) | 2018-02-02 | 2023-07-18 | 勃林格殷格翰国际有限公司 | 作为饥饿素o-酰基转移酶(goat)抑制剂的噁二唑并吡啶衍生物 |
| JP7083397B2 (ja) | 2018-02-02 | 2022-06-10 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | グレリンｏ－アシルトランスフェラーゼ（ｇｏａｔ）阻害剤として使用するためのトリアゾロピリミジン誘導体 |
| CN111349155B (zh) * | 2018-12-24 | 2022-04-05 | 浙江和泽医药科技股份有限公司 | 一种胰高血糖素类似物及其制备方法和用途 |
| TWI771669B (zh) | 2019-04-26 | 2022-07-21 | 美商美國禮來大藥廠 | 製備穩定胜肽調配物之方法 |
| PH12022551101A1 (en) | 2019-11-11 | 2023-11-13 | Boehringer Ingelheim Int | Npy2 receptor agonists |
| ES2984466T3 (es) | 2020-05-22 | 2024-10-29 | Boehringer Ingelheim Int | Procedimiento de fabricación de 7-amino-5-metil-[1,2,5]oxadiazolo[3,4-b]piridín-carboxilato de alquilo |
| CN115916789B (zh) | 2020-05-22 | 2025-06-27 | 勃林格殷格翰国际有限公司 | 制备烷基7-氨基-5-甲基-[1,2,5]噁二唑并[3,4-b]吡啶羧酸酯的连续方法 |
| CN113278060B (zh) * | 2020-05-29 | 2022-03-25 | 东莞云璟生物技术有限公司 | Glp-1/胰高血糖素双重激动剂融合蛋白 |
| WO2022029231A1 (en) | 2020-08-07 | 2022-02-10 | Boehringer Ingelheim International Gmbh | Soluble npy2 receptor agonists |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK0929567T3 (da) | 1996-09-09 | 2005-06-27 | Zealand Pharma As | Forbedret fastfase-peptidsyntese og middel til anvendelse af en sådan syntese |
| CA2321026A1 (en) | 1998-03-09 | 1999-09-16 | Zealand Pharmaceuticals A/S | Pharmacologically active peptide conjugates having a reduced tendency towards enzymatic hydrolysis |
| EP1076066A1 (en) | 1999-07-12 | 2001-02-14 | Zealand Pharmaceuticals A/S | Peptides for lowering blood glucose levels |
| GB0121709D0 (en) | 2001-09-07 | 2001-10-31 | Imp College Innovations Ltd | Food inhibition agent |
| PL1891105T3 (pl) | 2005-06-13 | 2012-09-28 | Imperial Innovations Ltd | Analogi oksyntomoduliny i ich wpływ na zachowania żywieniowe |
| WO2007100535A2 (en) | 2006-02-22 | 2007-09-07 | Merck & Co., Inc. | Oxyntomodulin derivatives |
| ZA200900545B (en) | 2006-07-18 | 2010-03-31 | Sanofi Aventis | Antagonist antibody against EPHA2 for the treatment of cancer |
| JP6017754B2 (ja) | 2007-02-15 | 2016-11-02 | インディアナ ユニバーシティー リサーチ アンド テクノロジー コーポレーションＩｎｄｉａｎａ Ｕｎｉｖｅｒｓｉｔｙ Ｒｅｓｅａｒｃｈ Ａｎｄ Ｔｅｃｈｎｏｌｏｇｙ Ｃｏｒｐｏｒａｔｉｏｎ | グルカゴン／ｇｌｐ−１受容体コアゴニスト |
| ATE520714T1 (de) | 2007-06-15 | 2011-09-15 | Zealand Pharma As | Glucagonanaloga |
| EP2307037A4 (en) | 2008-06-17 | 2011-08-03 | Univ Indiana Res & Tech Corp | GLUCAGON ANALOGUE WITH IMPROVED SOLUBILITY AND STABILITY IN PHYSIOLOGICAL PH BUFFERS |
| CA2728284C (en) | 2008-06-17 | 2019-09-10 | Richard D. Dimarchi | Glucagon/glp-1 receptor co-agonists |
| PL2370462T3 (pl) * | 2008-12-15 | 2015-01-30 | Zealand Pharma As | Analogi glukagonu |
| US9156901B2 (en) * | 2009-07-13 | 2015-10-13 | Ditte Riber | Acylated glucagon analogues |
| NZ601167A (en) * | 2010-01-20 | 2014-12-24 | Zealand Pharma As | Treatment of cardiac conditions |
| UY33462A (es) * | 2010-06-23 | 2012-01-31 | Zealand Pharma As | Analogos de glucagon |
-
2012
- 2012-12-19 EA EA201490982A patent/EA201490982A1/ru unknown
- 2012-12-19 WO PCT/EP2012/076137 patent/WO2013092703A2/en not_active Ceased
- 2012-12-19 PE PE2014000970A patent/PE20142113A1/es not_active Application Discontinuation
- 2012-12-19 SG SG11201403377QA patent/SG11201403377QA/en unknown
- 2012-12-19 US US13/720,041 patent/US20130316941A1/en not_active Abandoned
- 2012-12-19 AP AP2014007797A patent/AP2014007797A0/xx unknown
- 2012-12-19 AU AU2012357739A patent/AU2012357739A1/en not_active Abandoned
- 2012-12-19 EP EP12816470.4A patent/EP2793931A2/en not_active Withdrawn
- 2012-12-19 KR KR1020147020623A patent/KR20140114845A/ko not_active Withdrawn
- 2012-12-19 IN IN4401CHN2014 patent/IN2014CN04401A/en unknown
- 2012-12-19 CA CA2858949A patent/CA2858949A1/en not_active Abandoned
- 2012-12-19 HK HK15101109.9A patent/HK1200369A1/xx unknown
- 2012-12-19 JP JP2014547973A patent/JP2015502380A/ja active Pending
- 2012-12-19 MX MX2014007120A patent/MX2014007120A/es unknown
- 2012-12-19 BR BR112014015681A patent/BR112014015681A2/pt not_active IP Right Cessation
- 2012-12-19 CN CN201280063090.8A patent/CN104144696A/zh active Pending
-
2014
- 2014-05-21 TN TNP2014000224A patent/TN2014000224A1/en unknown
- 2014-05-26 IL IL232800A patent/IL232800A0/en unknown
- 2014-06-11 PH PH12014501336A patent/PH12014501336A1/en unknown
- 2014-07-09 AP AP2014007774A patent/AP2014007774A0/xx unknown
- 2014-07-11 MA MA37205A patent/MA35864B1/fr unknown
-
2016
- 2016-08-17 US US15/239,154 patent/US20160347813A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| AP2014007797A0 (en) | 2014-07-31 |
| PH12014501336A1 (en) | 2014-09-15 |
| HK1200369A1 (en) | 2015-10-09 |
| WO2013092703A3 (en) | 2013-11-14 |
| BR112014015681A2 (pt) | 2019-09-24 |
| KR20140114845A (ko) | 2014-09-29 |
| WO2013092703A2 (en) | 2013-06-27 |
| SG11201403377QA (en) | 2014-07-30 |
| US20130316941A1 (en) | 2013-11-28 |
| IN2014CN04401A (OSRAM) | 2015-09-04 |
| US20160347813A1 (en) | 2016-12-01 |
| IL232800A0 (en) | 2014-07-31 |
| JP2015502380A (ja) | 2015-01-22 |
| EP2793931A2 (en) | 2014-10-29 |
| TN2014000224A1 (en) | 2015-09-30 |
| MX2014007120A (es) | 2015-03-05 |
| AP2014007774A0 (en) | 2014-07-31 |
| EA201490982A1 (ru) | 2015-01-30 |
| MA35864B1 (fr) | 2014-12-01 |
| CN104144696A (zh) | 2014-11-12 |
| AU2012357739A1 (en) | 2014-07-03 |
| CA2858949A1 (en) | 2013-06-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE20142113A1 (es) | Analogos de glucagon | |
| AR094180A1 (es) | Derivados de exendina-4 | |
| AR098739A1 (es) | Análogos del péptido exendina-4 como agonistas duales del receptor de glp-1 / glp (péptido similar al glucagón tipo 1 / glucagón) | |
| AR098737A1 (es) | Agonistas duales del receptor de glp-1 / gip | |
| PE20130326A1 (es) | Analogos de glucagon | |
| AR099976A1 (es) | Agonistas peptídicos duales de los receptores de glp-1 / glucagón derivados de la exendina-4 | |
| AR098740A1 (es) | Análogos del péptido exendina-4 | |
| AR092873A1 (es) | Peptidos como agonistas triples de los receptores de gip, glp-1 y glugagon | |
| PE20130338A1 (es) | Analogos del glucagon | |
| PE20140969A1 (es) | Combinacion de analogos del glucagon acilados con analogos de insulina | |
| PE20231639A1 (es) | Compuestos co-agonistas del glucagon y peptido-1 similar al glugacon (glp-1) | |
| AR091866A1 (es) | Analogos del glucagon | |
| AR099975A1 (es) | Derivados de exendina-4 como agonistas peptídicos duales del receptor de glp-1 / glucagón | |
| TN2012000215A1 (en) | Pharmaceutical compositions comprising a g l p -1 agonist and methionine | |
| AR096440A1 (es) | Compuesto peptídico agonista del receptor del péptido similar al glucagón tipo i (glp-1) y del péptido insulinotrópico dependiente de glucosa (gip) | |
| PE20211300A1 (es) | Peptidos y combinacion de peptidos de origen no canonico para el uso en la inmunoterapia contra diferentes tipos de cancer | |
| NZ589847A (en) | Glucagon/glp-1 receptor co-agonists | |
| PE20121130A1 (es) | Analogos de glucagon acilados | |
| MX366405B (es) | Uso de peptidos glp-1 de accion prolongada. | |
| AR098741A1 (es) | Agonistas duales del receptor de glp-1 (péptido similar al glucagón 1) / glucagón | |
| AR067555A1 (es) | Derivado de peptido insulinotropico en el cual se modifica su aminoacido n- terminal | |
| NI201100213A (es) | Péptidos específicos para receptores de melanocortina | |
| PE20140724A1 (es) | Coagonistas del receptor de glucagon/glp-1 | |
| MX377410B (es) | Antagonistas de receptores de integrina y sus metodos de uso. | |
| CL2011001498A1 (es) | Profarmaco que comprende la estructura a-b-q donde q es un peptido de la superfamilia de glucagon, a es un aminoacido o un hidroxiacido y b es un aminoacido n-alquilado ligado a q; composicion farmaceutica que comprende el profarmaco; metodo para suprimir el apetito o inducir la perdida de peso. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA | Abandonment or withdrawal |